Assuntos
Proteínas de Fusão bcr-abl/genética , Janus Quinase 2/genética , Mutação , Transtornos Mieloproliferativos/genética , Translocação Genética , Substituição de Aminoácidos , Proteínas de Fusão bcr-abl/metabolismo , Humanos , Janus Quinase 2/metabolismo , Transtornos Mieloproliferativos/metabolismoRESUMO
We here report a male patient with an additional t(3;21)(q26;q22) in Philadelphia positive chronic myelogenous leukemia (Ph + CML). In spite of the presence of this progression of disease marker and probably related to alpha-interferon therapy, this case entered into remission as a second chronic phase. At that time, he underwent allogeneic bone marrow transplantation. One year after BMT he showed a disappearance of leukemic clones at the cytogenetic and molecular levels. At present the patient has 21 months of clinical and hematologic remission. It is of interest to note that the association of alpha-interferon-hydroxyurea and bone marrow transplantation might produce a negative selection pressure against the leukemic clone in this patient.
